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Abstract
Nanomedicine plays an important role in the diagnosis, treatment, monitor-
ing and control of biological systems in the area of nanotechnology and has been 
referred by the National Institute of Health (NIH) as an emergent way of medicine. 
Nanoparticles are new delivery vehicles with the ability to release drugs to a specific 
cell type or tissue, which may also improve the pharmacological activity of those 
drugs by controlling their release, as well as prolonging their short half-lives in 
blood. The aim of this review is to gather several options of MOFs and nanotubes 
synthesised with different nanoparticles and processes, some including compound 
loading and release studies, with particular focus on 13 anti-cancer compounds 
e.g. doxorubicin, curcumin, methotrexate, etc.; 3 anti-inflammatory compounds, 
namely ibuprofen, salicylic acid and chlorogenic acid; and with 5 miscellaneous 
bioactive compounds, including rifampicin, griseofulvin, enoxacin, etc. Finally, 
other biomedical applications for these composites are shown, like being enzyme 
immobilisation agents, for water treatment e.g. in swimming pools, and other 
becoming support to carry & secure integrity of drugs.
Keywords: nano MOFs, nanotubes, drug delivery, biomedical applications, 
composite materials
1. Introduction
Any material could be described as a (semi) solid entity, substance or device that 
things could be made from, with the purpose to resolve a present or future need. 
There are a lot of daily examples that we are able define as materials, for instance, 
cloth, wood and electronic devices, such as computers, cell phones and smart TVs. 
Materials could be divided into natural and synthetic groups and, at the same time, 
they are commonly classified depending on their composition or physicochemical 
properties. Nowadays, the search for synthetic materials has been fast growing, 
because of their electrical, thermal, mechanical, structural and in many cases, their 
emergent properties, that make them suitable for many fields of science.
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In recent years, the development and modification of materials at the nanoscale 
for biomedical purposes has been extensively reported in the literature. One of the 
most significant of these has been the encapsulation or capture of drugs with the 
purpose of increasing dosage, providing protection against body’s metabolism and 
directing the drug to the therapeutic target or a specific site. Despite these benefits, 
the principal limitations include the host-guest compatibility, very closely related 
with toxicity, the degradation and the half-life of the nanomaterial. For this reason, 
these side studies should be included when a new material is developed for biomedi-
cal purposes.
Metal Organic Frameworks (MOFs) are a class of microporous 1D, 2D or 3D 
crystalline materials, constructed from a metal ion held together by organic poly-
functional ligands, that confer special characteristics to this arrangement. Some 
of these features are their high/tunable surface area, homogenous porosity, their 
great stability and crystallinity, among other. Due to these characteristics, MOFs are 
widely applied in the storage and separation of gases, as sensors, and in matrices to 
capture/deliver a large amount of several kinds of molecules and in particular drugs 
even showing specificity towards therapeutic targets and thus improving the effect 
of the drugs and their bioavailability.
Besides, nanotubes have the potential to revolutionise biomedical research, 
due to their important electrical, chemical, thermal, mechanical and structural 
properties which have made them an area of great research interest. With this in 
mind, they are capable to display metallic, semiconducting and superconducting 
electron transport properties. Although carbon nanotubes (CNTs) are the most 
common, they also could be constructed from peptides and organometallic moieties 
or materials. The CNTs could be used in numerous applications, including nano-
fluidic systems, biopharmaceutical applications such as drug delivery, implantable 
biomedical devices, diagnostic tools and devices in radiation oncology, biosensors, 
probes and quantum dots, such as nanosensors and nanorobots and also for tissue 
engineering applications [1].
Hence, the gathering criteria of all these research examples in this chapter is 
focused on evidencing some of the most relevant examples from the last 5 years 
(2014–2018) in terms of nanomaterials, with capability to act as (i) drug delivery 
systems and for (ii) general biomedical applications, addressing aspects such as 
the composition of these materials, type of loaded/tested/delivered drugs interact-
ing with both, (nano) MOFs or nanotube materials and their perspectives on the 
synthesis and modification of these new composites for such applicability.
2. Drug delivery
2.1 Anti-cancer
In this first contribution, the MIL-100(Fe) was prepared using a hydrothermal 
microwave-assisted method. Synthetic procedure required a mixture of FeCl3 
hexahydrate and 1,3,5-benzenetricarboxylic acid settled in deionised water, which 
was heated at 130°C during a period of 6 min. The characterisation of the crystal-
line substance was performed by X-ray powder diffraction (XRPD), meanwhile 
particle size and morphology were determined by Dynamic Light Scattering (DLS) 
and Transmission Electron Microscopy (TEM). Additionally, surface morphology 
was characterised using Field-Emission Scanning Electron Microscopy (FESEM) 
and the pore size was determined by nitrogen sorption experiments. The measured 
Langmuir surface was of 1350 ± 100 m2 g−1. The pore size of this material measured 
a free diameter of ca. 25 and 29 Å, which is accessible through the pentagonal and 
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hexagonal microporous windows present in this material (5.5 and 8.6 Å). The 
incorporation of doxorubicin (DOXO) in MIL-100(Fe) was determined by UV-Vis, 
circular dichroism (CD) and fluorescence spectroscopies, and the determined 
concentration of DOXO present in this material was 9 wt% (Figure 1) [2].
In this other piece of work, Gemcitabine-5′-monophosphate (Gem-MP) 
was appropriately loaded into MIL-100(Fe) MOF material, reaching a top con-
centration of 30.7 ± 0.8 wt%; this was confirmed by High Performance Liquid 
Chromatography (HPLC) and radioactivity counting methods (Figure 2). The 
Gem-MP@MIL-100(Fe) release studies were performed in PBS media and 100% 
of release of this drug molecule was reached at 4 h. The Half Maximal Inhibitory 
Concentration (IC50) of both empty and loaded materials were tested in pancreatic 
cancer cell lines (PANC-1) using the MTT method. This experiment has shown 
that the unloaded material had no effect on the viability of cells. However, when 
Gem-MP and Gem-MP@MIL-100(Fe) were tested, the IC50 were 17.5 μM and 
45 nM, respectively. This finding clearly confirmed that the activity of Gem-MP is 
improved ca. 389 times when it is loaded into MIL-100(Fe) material [3].
Moreover, a phytochemical-ligand-containing metal-organic framework of the 
formula {[Zn2(fer)2]}n, (Zn-fer MOF) was prepared, where the organic ligand 
named H2fer = ferulic acid, and its structural elucidation revealed the presence of 
large nanocage-based pores suitable for ionic or molecular guest incorporation. 
With the latter in mind, Zn-fer MOF was employed as interaction matrix for the 
adsorption and in vitro carriage of 5-fluorouracil (5-FU), obtaining 5-FU@Zn-fer 
material. The ability of 5-FU@Zn-fer to deliver 5-FU, biodegradation and cytotoxic-
ity assays were also determined. Additionally, the grand canonical ensemble Monte 
Carlo (GCMC) simulation was performed to in silico investigate the loading of 
5-FU to Zn-fer at the molecular level. With these results, authors determined that 
5-FU could be adsorbed into this BioMOF with a high loading. GCMC simulations 
validated the experimental trend, showing that 5-FU could be incorporated into de-
solvated Zn-fer MOF reaching loadings as high as 0.388 g g−1. The analysis of radial 
distribution function (RDF) and configuration snapshot analysis, showed that the 
most important interaction between 5-FU and Zn-fer MOF are hydrogen bonding 
and dipolar interactions (Figure 3). Furthermore, the delivery of 5-FU occurred 
within 100 h and at that time, 99% of the loaded drug was already released. For 
further sights, this may lead to the desired modulated release of anti-cancer agents 
over a long-time and probably reducing side-effects for patients. Finally, according 
Figure 1. 
MIL-100 (Fe)/DOX [2].
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to our criteria, this investigation has provided impetus to design and develop similar 
structured biocompatible MOFs which are able to offer relatively superior drug 
carrying and drug release properties [4].
Some other investigation aims for the incorporation of target molecules based 
on a multistep post-functionalization procedure. In the cited research, the authors 
report a novel approach combining MOF synthesis and molecule encapsulation 
in a one-pot process. Researchers have therein demonstrated that large molecules 
are appropriate to be entrapment in the composite zeolitic imidazolate framework 
(ZIF). The distribution was homogeneous into the ZIF, and in this way their 
Figure 2. 
Representation of Gem-MP encapsulation into MIL-100(Fe) [3].
Figure 3. 
The density of 5-FU under 10-5 mPa, 1 mPa for (a) and (b) (top pictures) and the snapshot of 5-FU in  
Znfer-MOF for (c) and (d) (down pictures) [4].
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loadings could be improvement. The ZIF-8 crystals were carried with DOXO to 
obtain DOXO@ZIF-8 composites, like efficient drug delivery vehicles for cancer 
therapy using pH-dependent release (Figure 4). The DOXO@ZIF-8 showed higher 
efficiency than DOXO against breast cancer cell lines, due to well-known composite 
enhancements. This one-pot process opens new possibilities to construct multifunc-
tional delivery systems for a wide range of applications [5].
The incorporation of drugs in biodegradable polymeric particles is one of many 
processes that controllably and significantly increase their release and action. The 
synthesis and physicochemical characterisation of ZnBDC-MOF (MOF-5) + DOXO 
giving place to DOXO@ZnBDC hybrid, and the effectiveness of this composite in 
the sustained release of the DOXO drug has been described. In a first procedure, the 
MOF-5 was obtained by mixing sodium terephthalate (Na2BDC), Zn(NO3)2·6H2O 
and H2O; the suspension was then transferred to a CEM (Microwave reactor) 
S-Class System with vessel temperature set at 120°C. The loading of DOXO into 
MOF-5 was performed by stirring 0.034 g of the dehydrated MOF-5 powder in 
4 mL of aqueous solution containing 0.1 g of DOXO during 1 day interaction 
period. An experimental and theoretical study is presented of the interaction 
between the MOF-5 material and DOXO molecule (Figure 5). The synthesis was 
carried on, and the resulting material was characterised by elemental analysis and 
XRPD. The experimental incorporation was accomplished and analysed by Fourier 
Transform Infrared Spectroscopy (FTIR) and UV-Vis spectroscopies, as well as by 
XRPD. An analysis of the adsorption of the DOXO@ZnBDC system confirmed the 
successful incorporation of the drug, revealing 0.0163 g of DOXO included into 
the composite, or an equivalent to 96% of the drug. The stability and drug release 
profile of DOXO@ZnBDC confirmed that the system released DOXO in a sustained 
or bimodal manner, like other systems, releasing 51.4% of the DOXO molecule in 
48 h. The behaviour described in the article demonstrates that the DOXO@ZnBDC 
system has the potential against cytotoxic cancer cell lines NCI-H292 (human pul-
monary mucoepidermoid carcinoma), HT-29 (human colorectal adenocarcinoma) 
and MCF-7 (human breast adenocarcinoma). The cytotoxic effect, an intensity 
scale for the cytotoxic potential of the system under study, was as stated in the 
following tendency related to cell growth inhibition [CGI], zero activity, ranging 
from 1 to 20%; little activity, 20–50%; moderate activity, 50–70%; and significant 
activity, 70–100%. In vitro cytotoxicity of unloaded MOF-5 was HT29 CGI = 72.6%, 
MCF-7 CGI = 47.4%, NCI-H-292 CGI = 77.0%; for free DOXO, HT29 CGI = 57.0%, 
MCF-7 CGI = 55.2%, NCI-H-292 CGI = 76.3%; and for DOXO@ZnBDC was 
HT29 CGI = 70.7%; MCF-7 CGI = 20.1%; NCI-H-292 CGI = 26.4% at different 
Figure 4. 
Distribution of mesopores in DOX@ZIF-8 particles illustrated by electron tomography. (a) TEM image of a 
DOX@ZIF-8 single crystal. (b) Cross-section of the electron tomogram with the mesopores marked by blue 
lines. (c) 3D distribution of the mesopores in the DOX@ZIF-8 particles [5].
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concentrations after 72 h. As can be seen, the MCF-7 & NCI-H-292 proved to be the 
most sensitive strains, because of the activity of composite material [6].
Another work of ZIF-8 crystal as a functional material was used to control the 
release of an autophagy inhibitor, 3-methyladenine (3-MA), and avoid the decom-
position of large quantities of the drug and enhance their bioavailability (Figure 6). 
The HeLa cells treated with 3-MA@ZIF-8 NPs has shown that the autophagosome 
development was successfully blocked. The pH-sensitive dissociation rises the 
efficiency of autophagy inhibition at the same concentration of 3-MA. In vivo test 
data showed higher efficacy to repress the expression of autophagy-related mark-
ers, Beclin 1 and LC3, in 3-MA@ZIF-8 NPs more than free 3-MA. Some of the most 
important features underlined by the authors is that ZIF-8 resulted an efficient drug 
delivery vehicle in antitumor therapy, especially in inhibiting autophagy of cancer 
cells. The cytotoxicity of 3-MA@ZIF-8 nanoparticles was evaluated by determining 
cellular viability through an MTT assay. The 3-MA@ZIF-8 NPs system was found to 
be toxic to HeLa cells in a dose-dependent manner, after treatment at a concentra-
tion of 7.5 μg mL−1 (equivalent to a concentration of 3-MA of 1.5 μg mL−1) for 24 h. 
The values were even lower after the cells had been treated with 3-MA@ZIF-8 NPs 
at a concentration of 10 μg mL−1 [7].
Following the versatility of ZIF-8 system, in other studies, DOXO was loaded 
into this MOF via a one pot process. The in situ loading process implied the water 
dissolution of the DOXO bioactive at 4 mg mL−1, then 0.2 g (0.66 mmol) of 
Zn(NO3)2·6H2O were dissolved in 0.8 mL of water, into which 4 mL of DOXO 
solution was added. After that 2 g of 2-methylimidazole were dissolved in 8 mL 
water and this was slowly dropped into the previous mixture. The in situ assembled 
DOXO@ZIF-8 composite was then coated with polydopamine, successively chelated 
with Fe3+ and conjugated with hyaluronic acid (HA). Finally, all these resulted in 
a multifunctional ZIF-8 nanocarrier of DOXO@ZIF@HA nature (Figure 7). The 
Figure 5. 
Simulated adsorption of the DOXO in surface of MOF by means of PM6 calculation [6].
Figure 6. 
Schematic representation of 3-MA@ZIF-8 [7].
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characterisation results confirmed the successful formation of the hybrid nanocar-
rier. The loading efficacy was determined to be 8.92 ± 0.53%. The data suggest that 
the release of DOXO from the nanocarrier demonstrated a sustained nature, but 
in this case regardless of the pH value. The cumulative amount of DOXO released 
at pH 5.0 and 7.4 was 70.1 and 9.8%, respectively, clearly showing a pH dependent 
behavior. The results of flow cytometry and confocal laser scanning microscope 
shown the targeting ability of DOXO@ZIF-HA towards prostate cancer PC-3 cells. 
In order to make notice the effect of composite assembly, the therapeutic efficacy of 
DOXO@ZIF-HA was clearly improved when compared with free DOXO. The cells 
were treated with different formulations of free DOXO and DOXO@ZIF-HA for 
24 h and untreated cells were used as a control. At a DOXO concentration of 1 mg 
mL−1, the cell viability for free DOXO and DOXO@ZIF-HA was 65.61 and 48.59%, 
respectively. This is mainly since the efficient internalisation of the targeted car-
rier DOXO@ZIF-HA could improve the intracellular DOXO concentration. Hence, 
authors state that the constructed ZIF-8 based multifunctional nanocarrier could be 
a candidate for cancer theranostics [8].
Another method to effectively carry DOXO to the breast cancer sites is the use 
of halloysite nanotubes (HNTs) coated with poly(ethylene glycol) (PEG) and 
folate (HNTs-PEG-FA), which have been used as drug delivery systems. The HNTs 
were reduced to ∼200 nm by ultrasonic scission and then functionalised with 
N-hydroxylsuccinimide-polyethylene glycol carboxylic acid (NHS-PEG-COOH) 
and folate (FA) moieties. The DOXO@HNTs-PEG-FA was prepared by filling 
with DOXO on HNTs-PEG-FA via physical adsorption (Figure 8). The maximum 
release of DOXO from DOXO@HNTs-PEG-FA was reached to 35 h at pH 5.3. The 
DOXO@HNTs-PEG-FA ensemble showed significant inhibition of proliferation 
and induction of apoptosis in MCF-7 cells with positive FA receptors but this is 
not true for L02 cells without FA receptors. The in vivo anti-breast cancer activity 
of DOXO@HNTs-PEG-FA was confirmed using 4T1-bearing mice. The DOXO@
HNTs-PEG-FA reduced toxicity and inhibited tumour growth associated with 
higher levels of caspase-3 protein. These results suggest that FA-conjugated HNTs 
may be designed to be a novel drug delivery system for targeted therapy of breast 
cancer via intravenous [9].
Figure 7. 
Diagram for the preparation of DOX@ZIF-HA and the Fe3+-mediated coordination interaction between HA 
and PDA [8].
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Another drug delivery strategy is when some peptides were used in the synthe-
sis of nanotubes capable of this method of carrying. Nanotubes was synthetized 
using two dipeptides based on their flexibility, one of them using the Phe-Phe 
backbone (βPhe-Phe and βPhe-ΔPhe); containing βPhe amino acid, and the other 
containing βPhe like a backbone constraining ΔPhe (α,β-dehydrophenylalanine) 
amino acid. Both were characterised by X-ray diffraction, DLS, TEM, FTIR and 
CD. Small drugs like riboflavin, DOXO, chloramphenicol and chloroquine, were 
tested in encapsulation experiments in these new nanotubes. The results have 
shown comparable encapsulation in both types of nanotubes, and the loaded 
contents were 7, 15, 35 and 18%, respectively. Moreover, these dipeptides have not 
shown cytotoxicity towards HeLa (cervical uterine cancer), B6F10 (melanoma 
mouse) and L-929 (fibroblast mouse) cells with different concentrations of 
peptide nanostructure. Mitoxantrone free and encapsulated in βPhe-Phe and βPhe-
Phe/βPhe-ΔPhe nanotubes was tested in equals amounts against cell lines HeLa 
and B6F10. The viability of HeLa cells treated with free mitoxantrone at 3 mg mL−1 
was 77%, while when encapsulated in βPhe-Phe or βPhe-ΔPhe nanotubes, the 
viability reduced to 58 and 53%, respectively. However, the value of viability for 
B6F10 cells changed from 85 to 60% and 31%, respectively. These results suggest 
that administration of mitoxantrone with dipeptide nanotubes was more effective 
against HeLa and B6F10 cancerous cells [10].
There are reports that by combining the advantage of multi-walled carbon 
nanotubes (MWCNTs) and interpolymer supramolecular complexes, a new carrier 
system consisting of poly (acrylic acid)/PEG/carbon nanotubes (PAA/PEG/CNT) 
has been assembled. The oxidised MWCNTs were obtained with nitric acid treat-
ment, yielding HOOC-MWCNTs, and then submitted to an activation reaction 
with SOCl2 to get MWCNT-COCl. The PEGylation of acyl chloride groups on the 
oxidised MWCNTs was completed by refluxing with PEG4000 and subsequently 
complexing with the second polymer (PAA). Then, methotrexate (MTX) and 
Figure 8. 
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cyclophosphamide (CPP) were loaded on PAA/PEG/CNT, and nanoparticles were 
characterised by FTIR, SEM, TGA and NMR. The efficiency of loaded drugs was 
determinate, an in vitro drug release study was carried out with UV spectroscopy 
in buffer human body (pH = 7.4) and buffer at pH of cancer cells (pH = 4). The in 
vitro release of drugs from nanoparticles showed an initial burst release followed by 
sustained release, this fact was due to the presence of the drug on the surface of the 
nanoparticles. The rate of release at this stage was very high and after 1 h, the drug 
concentration was constant [11].
Another kind of composite is based in the synthesis of the bio-compatible poly-
mer PEG-400 and MWCNTs. The MWCNTs were PEG-400-broken-assisted into 
small tubes by vortex mechanical mixing with tungsten-carbide balls for about 15 h. 
Length separation of MWCNTs was then carried out using differential centrifuga-
tion also PEG-400-assisted with various concentrations of the polyether. Novel 
cocoon nanoparticles of sizes ranging about 100–200 nm were observed in one 
of the centrifuged fractions. The cocoon pellets were re-dispersed in water using 
ultrasonication for 2 min and characterised using Field Emission SEM, TEM and 
FTIR. Energy Dispersive Spectroscopy (EDS) and diffraction patterns were also 
obtained using TEM. Curcumin (CUR) was added as the bioactive, anticancer drug, 
to these cocoons, and it was observed that it was distributed in these motifs while 
it was not attached to the CNT-PEG solution without cocoon structures (Figure 9). 
The cocoon and CUR@cocoon samples exhibited much lower haemolysis than CUR 
alone, with a value of 0.04, 0.03 and 0.09%, respectively. Also, it was observed that 
all cocoon and CUR@cocoon samples were non-toxic at the concentrations tested. 
The cell viability of CUR@cocoon samples were less than 95% at 50 μg, indicating 
cytotoxicity on L-929 cells at higher concentrations. The CUR@cocoon assemblies 
were dispersible in saline solution and could be internalised by brain cancer cells 
(C6 glioma), while free CUR dispersed in saline solution could not enter C6 glioma 
cells, this clearly evidenced differential diffusion and selectivity in this trial [12].
In this work was prepared HNT@CUR-Au/CS NPs by an in situ preparation. 
First, gold, HNTs and CUR were mixed to obtain HNT@CUR-Au and subse-
quently coating with bio-adhesive chitosan (CS). The HNT@CUR-Au/CS has been 
characterised by FTIR, XRPD, XPS and STEM methods (Figure 10). The loading 
efficiency of drug into the nanostructures was 12% at most. The release of the 
drug was more efficient under pH = 5.5 than pH = 7.4. The anticancer potential of 
HNT@CUR-Au/CS against MCF-7 cells shown more efficient anticancer activity in 
Figure 9. 
High resolution TEM of curcumin added to nano-cocoons [12].
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the intracellular environment than in extracellular conditions, in agreement with 
their own previous differential pH physicochemical CUR-release tests. Moreover, 
the development of this composite consisting of Au NPs and pH-responsive CUR 
release could make it suitable for cancer cell-targeted drug delivery platforms, also 
with the possibility to develop NIR-imaging [13].
In an another research group, a new design of hydroxypropyl-β-cyclodextrin 
(HP-β-CD) modified carboxylated single-walled carbon nanotube (CD-SWCNTs) 
assembly was employed to improve the biocompatibility and reduce the toxicity 
of the self-carbon nanotubes for the release of the anticancer drug formononetin 
(FMN). According to the analysis of results developed by the authors related to 
findings in FTIR, HP-β-CD was successfully grafted into carboxylated single-
walled carbon nanotubes (SWCNTs-COOH). The samples were characterised by 
XRPD, differential scanning calorimetry (DSC), DLS and SEM. The loading of 
FMN in CD-SWCNTs to develop FMN@CD-SWCNTs system was determined 
by HPLC. The entrapment efficiency and loading capacity were determinate to 
be 88.66 ± 3.13% and 8.43 ± 1.11%, respectively. The HP-β-CD system possesses a 
hydrophobic inner cavity and a hydrophilic exterior, which could bind/inner entrap 
hydrophobic drug molecules to form stable host-guest supramolecular assemblies. 
The SWCNTs have a high aspect ratio and surface area, and they could interact with 
FMN via π-π stacking interactions, which resulted in a high entrapment efficiency 
(Figure 11). The cumulative release of FMN from FMN@CD-SWCNTs nanocarrier 
achieved 4.11 ± 0.62% within 48 h at a pH = 5.3, compared with 16.75 ± 0.88% when 
exposed to pH = 7.4. This kind of drug release kinetics demonstrated a slow and 
sustained release, but in this particular case resulted more efficient at physiologic 
Figure 10. 
Schematic representation of formation of HNT@CUR-Au/CS [13].
Figure 11. 
Scheme of the possible interaction of FMN with CD-SWCNTs [14].
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pH, in comparison with other related systems. The in vitro cytotoxic activity of 
FMN@CD-SWCNTs nanocarriers against MCF-7 and HeLa cells was tested by 
using the WST-1 assay. The antitumour activity of FMN@CD-SWCNTs had an 
IC50 = 17.989 ± 1.255 and 21.775 ± 1.338 μmol L
−1 for MCF-7 and HeLa cells, respec-
tively. This latter was higher than that of lone FMN with an IC50 = 55.986 ± 2.479 
and 72.995 ± 0.551 μmol L−1 for MCF-7 and HeLa cells, respectively. These results 
confirm that FMN@CD-SWCNTs complexes exhibit a higher cytotoxic activity 
than free drug [14].
In this review, f-SWCNTs were used as the starting material to react with 
the anticancer drug betulinic acid (BA) to produce f-SWCNTs-BA conjugate 
via 𝜋-𝜋 stacking interactions. The BA@f-SWCNTs composite was assembled by 
dispersed f-SWCNT in a solution with BA in methanol and sonicated for 30 min. 
The BA@f-SWCNTs conjugate was characterised by XRPD, TGA, FE-SEM and 
FTIR spectroscopy to elucidate and quantify the concentration of the drug in 
BA@f-SWCNTs and the structure of the conjugate (Figure 12). The results indi-
cated that the drug loading capacity was around 20 wt%. The release of the drug 
from BA@f-SWCNTs was tested in a human body media at pH 7.4 and 4.8 value; 
this study has shown that the release rate of BA is higher in pH 7.4 than pH 4.8, 
again another example of controlled release but an higher pH values, and for this 
reason drug delivery resulted to behave pH-dependent. The maximum percent-
age release of BA reached 89.2% (24 h) and 78.7% (10 h) when exposed to pH 7.4 
and 4.8, respectively. The cytotoxicity assays for BA, f-SWCNT and conjugated 
BA@f-SWCNTs were performed in a healthy fibroblast cell line (3T3) and two 
cancer human lines, liver cancer (HepG2) and lung cancer (A549), at various 
concentrations ranging from 0.78 to 50 μg mL−1 at 72 h and were measured by 
the MTT method. The experiment has shown that at several doses the f-SWCNT 
did not have a significant impact on the viability of any cell lines. However, at 
a dose of 25 μg mL−1 of BA@f-SWCNTs, the viability of HepG2 and A549 were 
reduced by more than 50%, in comparison with lone BA that shown low cytotox-
icity at the same concentration [15].
Also, there are reports describing the preparation of a biocompatible and pH 
sensitive biodegradable hydroxyapatite material using mesoporous nanoplates 
(Hap PNPs) employing a hydrothermal technique with carboxymethylcellulose 
calcium salt. This material was characterised using FESEM; the length of spindle 
structures was 20 nm and the diameter was 10 nm on average, the specific area was 
180 m2 g−1 and a crystallite size of 17 nm was calculated using the Debye-Scherer 
equation. This material was tested as a nanocarrier, and the model loaded drugs 
were MTX and andrographolide. The UV-vis analysis confirmed that the HAp PNPs 
have a drug loading efficiency of 50–55.5% at pH = 7.0, which is greater than the 
conventional HAp nanostructure loading capacity, showing a sustained release at 
a pH = 4.4. The andrographolide anticancer drug was readily loaded onto prepared 
HAp PNPs and released in a pH-controlled manner, where for an acidic pH = 4.4 
Figure 12. 
Scheme for the functionalization of BA molecule onto the f-SWCNTs nanocarrier via π-π stacking interaction [15].
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the liberation is higher as compared with a pH of 7.0 or 9.0. The MTT assay was 
used for the determination of the cytotoxicity in A431 cell lines at different doses of 
HAp PNPs (0–1000 μg mL−1) and andrographolide loaded (25, 50, 75, 100, 125 and 
150 μM) on HAp PNPs (fixed concentration of 100 μg mL−1) at different pHs of 9.0, 
7.0 and 4.4 for 24 h. The results have shown that the prepared HAp PNPs exhibited 
biocompatibility at higher doses of 1000 μg mL−1. Also, they demonstrated that the 
cytotoxic effect increased by increasing the dose of andrographolide loaded HAp 
PNPs at pH = 9.0 with an IC50 = 125 μM [16].
In the next work nanotubes of SiO2 were prepared with a uniform diameter 
of 2.5 nm and shell thickness of 1–5 nm and the exterior surface was silane 
functionalised and had a negative charge; hence could be selectively loaded with 
compounds positively charges. The synthesis was carried out using (3-chloro-
propyl) trimethoxysilane (CPTMS) and tetraethylorthosilicate (TEOS). The 
characterisation was performed with TEM, X-ray spectroscopy elemental mapping 
and the particle size was determined by dynamic analysis. The concentration of 
organic material was quantified using FTIR. This material had a transmittance of 
aprox. 84% at 550 nm. The load of organic material was 63.6% and determinate by 
TGA. Positively charged DOXO was loaded in the material; 80% of material was 
released over 2 weeks, due to size of the elongated nanochannel that suppressed 
the diffusion [17].
2.2 Anti-inflammatory
Other method to prepare porous MOF materials is the union of an organic 
linker with other secondary building unit (SBU). For example [M2(COO)4] 
(M = Cu, Zn, Mn, Ni, etc.), [M3O(COO)6] (M = Fe, Ni, etc.), [Zn4O(COO)6] 
and [M6O4(OH)4(COO)12] (M = Zr, Hf) MOF systems. Calcium ion possess acid 
properties, large atom radii and large coordination number, for these reasons is not 
frequently found it in MOFs structures in comparation with other transition metal-
based MOFs. However, the assembly of calcium ions with a big triangle aromatic 
carboxylic acid ligand has been reported and resulted in a unique porous Ca-MOF 
structure with nano-sized {Ca11} carboxylate SBU and a 2D square channel with a 
size of 10.8 Å × 10.7 Å. The crystal structure was solved by single crystal X-ray dif-
fraction methods. To determine the thermal stability of the material TGA method 
was used, where it was found that a continuous slow weight loss was observed until 
550°C, the authors state that this should correspond to the release of the coordi-
nated water, at the beginning, and DMF molecules, later on at the thermogram. 
Drug molecular storage experiments revealed that the porous structure could be 
dosed with guaiacol molecules at a ratio of 0.19 g g−1; the molecular size of guaia-
col was 4.9 × 4.1 Å, which is smaller than the channel size of Ca-MOF. On the other 
hand, the same probes were made with ibuprofen. The TGA measurement for 
ibuprofen was performed as well; however, there was no obvious signal pointing to 
the residual of ibuprofen in the framework of Ca-MOF, since all the guest mol-
ecules in the sample were gone when the temperature was lower than 100°C. The 
drug release experiments were performed by guaiacol samples immersed in PBS 
solution (pH = 7) and the UV-Vis spectroscopy of the guaiacol release solution 
was monitored in situ for 24 h. The results showed that the guaiacol molecules 
were released slowly from Ca-MOF, and after 15 h the absorbance reached the 
maximum value, demonstrating a slow molecule release process and its potential 
application in medical use. Further work should explore the anionic property of 
the Ca-MOF, so the drug candidate would be extended from the neutral one to a 
cationic one, which may achieve the required drug release controlled by strong 
electro interaction [18].
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Halloysite (Hal), a clay mineral of the kaolin group, is of great interest due to a 
variety of its potential applications. Many Hal nanotubes were functionalised with 
a polyamidoamine (PAMAM) dendrimer to obtain polyamidoamine dendrimer-
functionalised halloysite nanotubes (Hal_PAMAM). These were obtained with 
single tube lengths between 200 and 1000 nm, the external diameter = 25–50 nm, 
internal diameter = 9–20 nm, these materials were characterised by FTIR, XRPD, 
TGA, SEM and TEM. The Hal_PAMAM was tested as a carrier of three different 
drugs, chlorogenic acid (CHLG), ibuprofen (IBU) and salicylic acid (SAL). The 
higher adsorption capacity was 123.16 mg g−1 for CHLG; 182.72 mg g−1 for IBU; 
39.52 mg g−1 for SAL as compared to raw halloysite and 3-aminopropyltrime-
thoxysilane (APTS) functionalised-halloysite nanotubes. As a result of surface 
functionalisation of halloysite with the dendrimer, the release rate of CHLG and 
SAL decreased, while the release profile of IBU was like that of APTS functionalised 
nanotubes. The accumulative CHLG release decreased from 90% for Hal to about 
55% for Hal_PAMAM, while the IBU release rates slowed down and for SAL the 
release rate decreased with respect to the other materials. The in vivo toxicity stud-
ies showed that the Hal_PAMAM had no effect on the living organisms used in the 
bioassays against Acutodesmus acuminatus and Daphnia magna [19].
Clay nanotubes are a nanomaterial carrier for sustained drug delivery that pro-
vide an extended 10–20 h release profile. These 50 nm diameter aluminosilicate 
tubes, with inner-alumina and outer-silica surface layers, could be loaded with 
10–30 wt% of drug molecules, DNA and enzymes (Figure 13). Clay nanotubes 
were evaluated for the delivery of different drug types, such as the anti-cancer 
drug Paclitaxel (release pattern initiation after 6 h, slow release over 24 h), and 
anti-inflammatory drugs such as SAL (burst 89% release within; then slow rate 
release over 100 min) and IBU (initial burst within 10 min; slow rate release over 
7 h) [20].
Novel nanohybrids have been used for the local release of drugs, particularly 
layered double hydroxides (LDHs), widely known as hydrotalcite-like compounds. 
These anionic clays are synthetic positively charged thin layer structures with 
exchangeable interlayer of anions. Many of these materials were synthesised with 
different molar ratios of Zn/Al-NO3 and Zn/Al-CO3 LDHs and were prepared by 
three different ion-exchange techniques. Three molar ratios were used: 0.3:1 to 0.5:1 
and 1:1. The resulting materials were intercalated with dexamethasone (DEXA) and 
deposited into nanotubes of anodised titanium (ATS-NL-1D), and the resulting 
nanotubes were characterised using FTIR and XRPD. The incorporation of DEXA 
anions in LDHs increased and this fact was confirmed by a diffraction lines d(003) 
to lower Ɵ with a maximum spacing from 8.9 to 15.09 Å, 16.70 and 21.215 Å for the 
nanohybrids, with a loading capacity of 12% (Figure 14). The test of cell viability 
revealed that the material was not toxic, the value of release of material was 80% 
of DEXA in 800 min, and the viability was 81.8% when this material was used for 
bone implants [21].
Figure 13. 
Scheme of drug molecules loading into clay nanotubes [20].
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2.3 Miscellaneous
Despite the increasing interest in MOFs for biomedical applications, the 
development of suitable formulations for different administration ways is still a 
major challenge. A simple, fast and bio-friendly press-moulding method has been 
proposed for the obtention of cutaneous patches using composites of MIL-100(Fe). 
The physicochemical properties of the patches implying structure, hydration, bio 
adhesivity, swelling properties, as well as their encapsulation and release capabili-
ties, both in ex vitro and ex vivo models were evaluated using different active ingre-
dients like challenging cosmetic liporeductor, caffeine and IBU. High concentrations 
of caffeine were taken up for these patches with sustained releases under experi-
mental cutaneous physiological conditions due the swelling of these devices. These 
patches afforded progressive and adequate permeation of their loaded molecules 
across the skin, reaching the adipose tissue. These characteristics make MOF-based 
patches as promising candidates for cosmetic applications (Figure 15) [22].
The Cu-BTC (BTC =1,3,5-benzenetricarboxylate) is a MOF considered the ideal 
porous framework in comparison with activated carbon due to its exceptional ther-
mal and mechanical stability. The ultrasound assisted synthesis of Cu-BTC nanopar-
ticles has been studied vs bulk Cu-BTC and activated carbon. To test the absorption 
capacity of the Cu-BTC for Rifampicin (Rif), a sample of Cu-BTC was put in an 
aqueous solution of Rif and the absorption was measured in real time with UV-vis 
technique. The samples were characterised with XRPD, SEM, FTIR and UV-vis spec-
troscopy. The adsorbed quantity of Rif over nano Cu-BTC (Rif@Cu-BTCNANO) 
was much higher (42.15 mg g−1) than those over a bulk Cu-BTC (Rif@Cu-BTC) 
(25.62 mg g−1) and activated carbon (18.85 mg g−1) (Figure 16). In compound Rif@
Cu-BTCNANO and all the nano-MOFs the channel length is decreased so that the 
amount of adsorption is increased a little. The delivery of Rif in ethanol increases 
with time, indicating that the Rif release is governed by the host-guest interaction. 
At 7 days of treatment, Rif release from Rif@Cu-BTCNANO, Rif@Cu-BTC and 
activated carbon was 78.47, 64.91 and 37.78%, respectively [23].
The direct incorporation of carboxylated carbon nanotubes (f-CNTs) into 
hydrophobic drug particles has been reported for the first time. The antifungal 
griseofulvin (GF) and the antibiotic sulfamethoxazole (SMZ) via anti-solvent pre-
cipitation, it consists that GF and SMZ were dissolved in acetone, and then added to 
a dispersion of f-CNTs in water, with the mixture turning cloudy when the crystals 
Figure 14. 
Schematic illustration of the nitrate layered double hydroxide before and after intercalation of DEXA [21].
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were formed. When f-CNTs were dispersed in water they acted as a nucleating site 
for the crystals and this fact allowed the rapid incorporation of the drug particles 
and increased the solubility. The time necessary to reach 80% dissolution (t80) of 
the drugs decreased from 67 to 10 min with the incorporation of 5.1% of f-CNTs in 
the case of SMZ. For GF, the decrease was from 66 to 18 minutes with the addition 
4% of f-CNTs (Figure 17) [24].
Also, there are nanotubes of carbon with cisplatin bonded that were synthesised 
and tested against promastigotes and amastigotes of Leishmania major. The cis-
platin was bonded to single walled (CP-SWCNT) and multiwalled (CP-MWCNT) 
carbon nanotubes, and both materials were evaluated using TEM and FTIR. The 
value of size was between 100 and 1000 nm in the longitudinal direction, and the 
diameter was <10 nm and <30 nm for CP-SWCNT and CP-MWCNT, respectively 
(Figure 18). The IC50 obtained with CP-SWCNT was 0.39 μM and for CP-MWCNT 
was 0.24 μM against promastigote, while against amastigote the IC50 was 0.17 and 
0.11 μM, respectively [25].
Figure 15. 
Schematic view of the composite patch preparation together with images of the different obtained patches [22].
Figure 16. 
(A) The pore of Cu-BTC. (B) Size of the Rif in comparison with pore size [23].
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Peripheral nerve injury (PNI) often results in a loss of sensory, motor, and auto-
nomic functions in the affected region. Current treatments depend largely upon 
surgical intervention, most popularly the use of autografts and allografts. For that 
reason, the use of HNTs to form a stronger chitosan-HNT composite structure has 
been investigated. HNTs with biodegradable chitosan were synthesised, with inter-
connected, longitudinally-aligned pores with an average size of 59.3 ± 14.2 μm. This 
material was used for sustained delivery of 4-aminopyridine (4-AP), to improve 
the rate of nerve regeneration. TGA profiles indicated a 7.69 wt% overall drug 
loading, compared with unmodified HNTs where average load is 5–10 wt%. On the 
first 7 days 30 ± 2% of encapsulated drug was release (Figure 19). In vivo studies 
carried out in Wistar rats with a primary focus on sciatic nerve studies showed an 
increase in strength and mobility over a period of 4 weeks after the implantation 
of 4-AP. Histological evaluation demonstrated biocompatibility and regeneration 
of the nerve. These studies demonstrated that the development of HNTs has a high 
potential to improve peripheral nerve regeneration and repair [26].
Titania nanotubes (Ti-NTs) have been proven to be good drug carriers and could 
release drugs efficiently around implants. Enoxacin (EN), an antibiotic with the pos-
sibility to be used for anti-osteoclastogenesis, was loaded into the Ti-NTs to obtain 
the complex Ti-NT + EN, and then was coated with type I collagen and HA to obtain 
Ti-NT + EN + Col/HA, both materials were characterised by X-ray photoelectron 
spectroscopy (XPS) (Figure 20). The results indicated that the loading efficiency 
of EN was 75% after the initial rinse. EN release was measured by HPLC and on the 
10th day the total amount of EN released by Ti-NT + EN and Ti-NT + EN + Col/HyA 
was 41.03 and 37.61 μg, respectively. Ti-NT + EN and Ti-NT + EN + Col/HyA were 
tested in the model of ovariectomised rats to evaluate the effect of osteogenesis and 
osteoclastogenesis. The results indicated that Ti-NT + EN + Col/HyA could promote 
osseointegration in ovariectomised rats better than Ti-NT + EN [27].
Figure 17. 
SEM images of (a) GF and (b) GF-CNTs [24].
Figure 18. 
TEM images of (a) CP-SWCNT and (b) CP-MWCNT [25].
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3. Biomedical applications
The HNTs have been widely used for controlled drug delivery, immobilisa-
tion of enzymes and for the capture of circulating tumour cells. These nanotubes 
were functionalised by two different organosilane reagents, Trimethoxy (propyl) 
silane (TMPS) and Triethoxy (octyl) silane (EOS), to improve their properties. 
Functionalisation was carried out by mixing HNTs and the organosilane reagent in 
acetone, and was heated at 50°C for 48 h. Both HNTs and their modifications were 
characterised by SEM, XRD, TGA and FTIR (Figure 21). The biocompatibility and 
cytotoxicity of these nanomaterials were determined using C6 rat glioblastoma 
cells. The results suggested that before being functionalised the nanotubes showed 
a high biocompatibility and low cytotoxicity. In contrast with their organosilane 
derivatives, increased cell mortality was observed after incubating under the same 
conditions [28].
Trichloroisocyanuric acid (TCCA) tablets are used for water treatment 
in swimming pools. This has been a widely used and safe way of releasing 
hypochlorous acid with wide biological capabilities, for instance, disinfectant, 
algaecide and bactericide application. The cited paper studied the incorpora-
tion of insect repellents (geranic acid, citronellic acid, geraniol and IR3535) 
in TCCA tablets with a simultaneous perfume/essence function. Although the 
mixture of TCCA with the repellents is not possible due to the incompatibility 
between both components, the researchers proposed a strategy of incorporation 
in silica and MOFs MIL-53(Al) and MIL-88A(Al) (Figure 22). The formulation 
of TCCA with the incorporated repellents resolved the incompatibility and 
produced a new tablet that could be used in water treatment, insect repellency 
and perfume [29].
Figure 19. 
Schematic of 4-AP drug loading into HNT, followed by sustained release of drug from lumne [26].
Figure 20. 
SEM images of the surface morphology of (A) Ti-NT and (B) Ti-NT + EN + Col/HyA [27].
Biochemical Toxicology - Heavy Metals and Nanomaterials
18
In this contribution, the authors defined that a well-controlled three-step green 
synthetic method allowed the synthesis of composite materials based on the highly 
stable chromium (III) terephthalate MIL-101(Cr) MOF with Au NPs and polyoxo-
metalates (POMs) inside its mesopores, developing (Au)POM@MOF ensembles. 
The strategy included, as a first step, the inclusion of POM into the MIL-101(Cr) 
cages by direct synthesis method of MIL-101(Cr) in the presence of H3PMo12O40 
(POM). Then, POM was reduced using H2 and finally a soft reduction of HAuCl4 
was performed to obtain Au NPs and oxidised POM into the MIL-101(Cr) structure 
[(Au)H2redPOM@101] (Figure 23). The final atomic ratio of 1.8 for Au/POM was 
reached. Characterisation studies revealed that the chemical and structural stabili-
ties of both MIL-101(Cr) and the POM were preserved during the whole process. 
Although the crystalline structure of the MOF was pre-served, the Au NPs were suc-
cessfully incorporated within the MOF and are strongly associated with the frame-
work, as confirmed by their exceptional stability under physiological conditions (cell 
culture medium). These results clearly underline the potential applications of these 
composites to the in situ formation of other interesting metal NPs within the pores of 
MOFs. In addition to the potential physicochemical properties of these highly porous 
composite systems, the authors state their promising performance as optical contrast 
agents. The (Au)H2red-POM@101 composites exhibited excellent biostability and 
were rapidly internalised in macrophage cells, as observed by fluorescence confocal 
microscopy. In this line, a suitable biological interaction was evidenced, as confirmed 
Figure 21. 
SEM images of (a) HNTs, (b) HNTs-TMPS and (c) HNTs-EOS [28].
Figure 22. 
Trichloroisocyanuric acid tablet [29].
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by the rapid cell internalisation of these (Au)POM@MOF composites. In addition, 
the previously proven important capacity to encapsulate and progressively release 
drugs from MOFs, together with the potential antitumoral and antiviral activity of 
POMs, make them interesting candidates in theranostics field [30].
In biotechnology, protein and especially enzyme immobilisation provides 
technical and economic advantages since the molecules could be used multiple 
times for the same reaction, demonstrating enhanced stability under extreme 
conditions of temperature, pH, salts and denaturing solvents. Therefore, they have 
longer half-lives since they degrade less and recover better and they are suitable 
for continuous processes. Conjugated protein-carbon nanotubes possess unique 
physicochemical properties that make them attractive to a wide range of applica-
tions. Thus, the effects of covalent conjugation of lysozymes with the activity and 
stability of SWCNTs were analysed. The carbodiimide method was used to coupling 
the lysozyme with SWCNTs (Figure 24). After the enzyme was analysed using 
fluorescence methods, plots of protein unfolding using different concentrations 
from 0 and 6 M of guanidine hydrochloride (Gn-HCl) were generated. Free lyso-
zyme showed a notable increase in the fluorescence value at 287 nm, besides to a red 
Figure 23. 
Schematic representation of (Au)POM@MOF [30].
Figure 24. 
SEM of conjugated lysozyme-SWCNTs (a) diameter of a bundle of lysozyme-SWCNTs = 2.5 μm, (b) average 
diameter of each conjugated lysozyme-SWCNTs = 95 nm [31].
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shift from 343 to 352 nm. The emission spectrum of conjugated lysozyme showed 
a substantial increase in the fluorescence at 287 nm and an important decrease 
in the value at 348 nm. These results support the important role of tryptophan 
and phenylalanine residues in the fluorescence of conjugated and free lysozymes. 
Kinetic parameters were observed in KM from 4.8 to 5.6 mM and Vmax from 193 to 
197 nmol min−1. The conjugated lysozyme showed a notable increase in pH stability 
from 3.0 to 10.0 at 70°C. The inactivation kinetic showed a behaviour of first-order 
for free and conjugated lysozymes when they were incubated for 10 min at 70°C 
obtaining a value of K = 0.139 min−1, in the presence of KCl and KSCN. The results 
of this study confirmed the excellent potential of the SWCNTs as a support for 
enzyme immobilisation [31].
4. Conclusions
In recent years the development of these composite materials has been grown 
due to their emergent biomedical applications. This 5 years survey evidenced that 
these materials have been employed with the intend to treat cancer, as anti-inflam-
matory agents, behaving as controlled-drug delivery systems or enzyme enhancers-
immobilisers, and other potential applications such as theranostics, also were 
found intends to develop combined therapeutics like photodynamic-chemotherapy, 
among other applications. Some of the most featured findings in this research gath-
ering revealed that even 2–3 orders of magnitude of efficacy have been determined 
for the loaded drug@material composites in comparison to the free drug state. 
Some other important features are that imidazolate materials resulted to be efficient 
drug delivery vehicles in antitumor therapy, especially in inhibiting autophagy 
of cancer cells. In general, it has been settled that acidic media is more feasible to 
release molecular contents of composites, but nevertheless this is also depending on 
chemical nature of composite itself, e.g. the physicochemical properties of drug as 
well as material confiner. Moreover, the broad applicability of these materials is just 
emerging, and we are going to presence very important developments in these lines 
in the near future.
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